NYSE:LLY - Eli Lilly And Co Stock Price, Price Target & More

Get Started

$82.80 +0.09 (+0.11 %)

(As of 05/25/2018 02:26 PM ET)

Previous Close$82.97

Today's Range$82.54 - $83.47

52-Week Range$73.69 - $89.09

Volume158,500 shs

Average Volume3.96 million shs

Market Capitalization$89.74 billion

P/E Ratio19.48

Dividend Yield2.72%

Beta0.26

About Eli Lilly And Co (NYSE:LLY)

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions. The company also provides neuroscience products for the treatment of depressive disorder, diabetic peripheral neuropathic pain, anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; schizophrenia; attention-deficit hyperactivity disorder; obsessive-compulsive disorder, bulimia nervosa, and panic disorder; and positron emission tomography imaging of beta-amyloid neurotic plaques in adult brains, as well as immunology products to treat Alzheimer's disease. In addition, it offers oncology products to treat non-small cell lung, colorectal, head and neck, pancreatic, metastatic breast, ovarian, bladder, and metastatic gastric cancers, as well as malignant pleural mesothelioma; and cardiovascular products to treat erectile dysfunction and benign prostatic hyperplasia; and migraine. Further, the company provides animal health products, such as cattle feed additives; protein supplements for cows; leanness and performance enhancers for swine and cattle; antibiotics to treat respiratory and other diseases in cattle, swine, and poultry; anticoccidial agents for poultry use; and chewable tablets that kill fleas and prevent heartworm diseases. Additionally, it offers vaccines to prevent bordetella, Lyme disease, rabies, and parvovirus. The company has collaboration agreements with Daiichi Sankyo Co., Ltd.; Incyte Corporation; Pfizer Inc.; AstraZeneca; and Nektar Therapeutics, as well as has strategic collaboration with Sigilon Therapeutics. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Receive LLY News and Ratings via Email

Sign-up to receive the latest news and ratings for LLY and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations

Sub-IndustryPharmaceuticals

SectorMedical

SymbolNYSE:LLY

CUSIP53245710

Webwww.lilly.com

Phone317-276-2000

Debt

Debt-to-Equity Ratio0.64

Current Ratio1.41

Quick Ratio1.01

Price-To-Earnings

Trailing P/E Ratio19.48

Forward P/E Ratio16.05

P/E Growth1.46

Sales & Book Value

Annual Sales$22.87 billion

Price / Sales3.93

Cash Flow$5.5459 per share

Price / Cash14.93

Book Value$13.44 per share

Price / Book6.16

Profitability

EPS (Most Recent Fiscal Year)$4.28

Net Income$-204,100,000.00

Net Margins4.82%

Return on Equity35.37%

Return on Assets11.30%

Miscellaneous

Employees40,655

Outstanding Shares1,085,430,000

Eli Lilly And Co (NYSE:LLY) Frequently Asked Questions

What is Eli Lilly And Co's stock symbol?

Eli Lilly And Co trades on the New York Stock Exchange (NYSE) under the ticker symbol "LLY."

How often does Eli Lilly And Co pay dividends? What is the dividend yield for Eli Lilly And Co?

Eli Lilly And Co declared a quarterly dividend on Monday, May 7th. Stockholders of record on Thursday, May 17th will be given a dividend of $0.5625 per share on Friday, June 8th. This represents a $2.25 dividend on an annualized basis and a dividend yield of 2.72%. The ex-dividend date of this dividend is Wednesday, May 16th. View Eli Lilly And Co's Dividend History.

How were Eli Lilly And Co's earnings last quarter?

Eli Lilly And Co (NYSE:LLY) released its quarterly earnings results on Tuesday, April, 24th. The company reported $1.34 earnings per share for the quarter, topping the consensus estimate of $1.13 by $0.21. The company had revenue of $5.70 billion for the quarter, compared to analysts' expectations of $5.51 billion. Eli Lilly And Co had a net margin of 4.82% and a return on equity of 35.37%. Eli Lilly And Co's quarterly revenue was up 9.0% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.98 earnings per share. View Eli Lilly And Co's Earnings History.

When is Eli Lilly And Co's next earnings date?

Eli Lilly And Co is scheduled to release their next quarterly earnings announcement on Tuesday, July, 24th 2018. View Earnings Estimates for Eli Lilly And Co.

What guidance has Eli Lilly And Co issued on next quarter's earnings?

Eli Lilly And Co updated its FY18 earnings guidance on Tuesday, April, 24th. The company provided EPS guidance of $5.10-5.20 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $4.87. The company issued revenue guidance of $23.7-24.2 billion, compared to the consensus revenue estimate of $23.43 billion.

What price target have analysts set for LLY?

18 analysts have issued 1-year price objectives for Eli Lilly And Co's stock. Their predictions range from $78.00 to $115.00. On average, they expect Eli Lilly And Co's share price to reach $93.8824 in the next twelve months. View Analyst Ratings for Eli Lilly And Co.

Who are some of Eli Lilly And Co's key competitors?

Some companies that are related to Eli Lilly And Co include Johnson & Johnson (JNJ), Pfizer (PFE), Novartis (NVS), AbbVie (ABBV), Merck & Co. (MRK), Novo Nordisk A/S (NVO), Abbott Laboratories (ABT), Bayer (BAYRY), GlaxoSmithKline (GSK), Sanofi (SNY), AstraZeneca (AZN), Bristol-Myers Squibb (BMY), Celgene (CELG), Allergan (AGN) and Shire (SHPG).

Who are Eli Lilly And Co's key executives?

Eli Lilly And Co's management team includes the folowing people:

Mr. David A. Ricks, Chairman, CEO & Pres (Age 50)
Dr. Jan M. Lundberg, Exec. VP of Science & Technology (Age 64)
Mr. Michael J. Harrington, Sr. VP & Gen. Counsel (Age 55)
Mr. Enrique A. Conterno, Sr. VP (Age 51)
Mr. Joshua L. Smiley, Sr. VP & CFO (Age 48)

Has Eli Lilly And Co been receiving favorable news coverage?

Headlines about LLY stock have trended somewhat positive on Friday, Accern reports. The research firm ranks the sentiment of media coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Eli Lilly And Co earned a news impact score of 0.09 on Accern's scale. They also assigned media stories about the company an impact score of 45.20 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the near term.

Who are Eli Lilly And Co's major shareholders?

Eli Lilly And Co's stock is owned by a variety of of institutional and retail investors. Top institutional investors include BlackRock Inc. (6.06%), PRIMECAP MANAGEMENT COMPANY (5.00%), Franklin Resources Inc. (3.00%), Northern Trust Corp (1.04%), Massachusetts Financial Services Co. MA (0.73%) and Legal & General Group Plc (0.43%). Company insiders that own Eli Lilly And Co stock include Alfonso G Zulueta, Derica W Rice, Donald A Zakrowski, Enrique A Conterno, Jackson P Tai, Jeffrey N Simmons, Joshua L Smiley, Lilly Endowment Inc, Maria A Crowe, Melissa S Barnes, Michael J Harrington, R David Hoover and Susan Mahony. View Institutional Ownership Trends for Eli Lilly And Co.

Which major investors are selling Eli Lilly And Co stock?

LLY stock was sold by a variety of institutional investors in the last quarter, including Westfield Capital Management Co. LP, Neuberger Berman Group LLC, Amundi Pioneer Asset Management Inc., Sei Investments Co., Northern Trust Corp, Massachusetts Financial Services Co. MA, Swiss National Bank and Eaton Vance Management. Company insiders that have sold Eli Lilly And Co company stock in the last year include Alfonso G Zulueta, Donald A Zakrowski, Jeffrey N Simmons, Joshua L Smiley, Lilly Endowment Inc, Melissa S Barnes, Michael J Harrington and Susan Mahony. View Insider Buying and Selling for Eli Lilly And Co.

Which major investors are buying Eli Lilly And Co stock?

LLY stock was purchased by a variety of institutional investors in the last quarter, including Franklin Resources Inc., Schroder Investment Management Group, BlackRock Inc., LSV Asset Management, Alps Advisors Inc., Mackay Shields LLC, Point72 Asset Management L.P. and Summit Trail Advisors LLC. Company insiders that have bought Eli Lilly And Co stock in the last two years include Jackson P Tai and R David Hoover. View Insider Buying and Selling for Eli Lilly And Co.

How do I buy shares of Eli Lilly And Co?

Shares of LLY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Eli Lilly And Co's stock price today?

One share of LLY stock can currently be purchased for approximately $82.84.

How big of a company is Eli Lilly And Co?

Eli Lilly And Co has a market capitalization of $89.74 billion and generates $22.87 billion in revenue each year. The company earns $-204,100,000.00 in net income (profit) each year or $4.28 on an earnings per share basis. Eli Lilly And Co employs 40,655 workers across the globe.

How can I contact Eli Lilly And Co?

Eli Lilly And Co's mailing address is LILLY CORPORATE CENTER, INDIANAPOLIS IN, 46285. The company can be reached via phone at 317-276-2000 or via email at [email protected]

MarketBeat Community Rating for Eli Lilly And Co (LLY)

Community Ranking:		2.8 out of 5 ( )
Outperform Votes:		771 (Vote Outperform)
Underperform Votes:		615 (Vote Underperform)
Total Votes:		1,386

MarketBeat's community ratings are surveys of what our community members think about Eli Lilly And Co and other stocks. Vote "Outperform" if you believe LLY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LLY will underperform the S&P 500 over the long term. You may vote once every thirty days.

Eli Lilly And Co (NYSE:LLY) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

18 Wall Street analysts have issued ratings and price targets for Eli Lilly And Co in the last 12 months. Their average twelve-month price target is $93.8824, suggesting that the stock has a possible upside of 13.38%. The high price target for LLY is $115.00 and the low price target for LLY is $78.00. There are currently 8 hold ratings and 10 buy ratings for the stock, resulting in a consensus rating of "Buy."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Buy	Buy	Hold	Buy
Consensus Rating Score:	2.56	2.58	2.47	2.53
Ratings Breakdown:	0 Sell Rating(s) 8 Hold Rating(s) 10 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 8 Hold Rating(s) 11 Buy Rating(s) 0 Strong Buy Rating(s)	1 Sell Rating(s) 7 Hold Rating(s) 9 Buy Rating(s) 0 Strong Buy Rating(s)	1 Sell Rating(s) 6 Hold Rating(s) 10 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$93.8824	$93.4444	$93.1176	$91.1875
Price Target Upside:	13.38% upside	14.03% upside	14.71% upside	9.19% upside

Eli Lilly And Co (NYSE:LLY) Consensus Price Target History

Price Target History for Eli Lilly And Co (NYSE:LLY)

Eli Lilly And Co (NYSE:LLY) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
5/22/2018	Barclays	Set Price Target	Buy	$98.00	Low
5/15/2018	Credit Suisse Group	Set Price Target	Hold	$82.00	Low
5/10/2018	BMO Capital Markets	Reiterated Rating	Hold	$78.00	Low
4/18/2018	HC Wainwright	Reiterated Rating	Buy		Low
4/13/2018	Jefferies Group	Set Price Target	Buy	$90.00	Low
2/26/2018	JPMorgan Chase & Co.	Set Price Target	Buy	$105.00	Medium
2/1/2018	Bank of America	Lower Price Target	Neutral ➝ Neutral	$88.00 ➝ $86.00	Low
1/16/2018	Goldman Sachs Group	Downgrade	Buy ➝ Neutral	$86.98 ➝ $95.00	High
1/5/2018	Argus	Upgrade	Hold ➝ Buy	$85.52 ➝ $115.00	Medium
11/21/2017	Morgan Stanley	Boost Price Target	Equal Weight ➝ Equal Weight	$86.00 ➝ $90.00	N/A
10/26/2017	Berenberg Bank	Reiterated Rating	Buy	$98.00	N/A
10/23/2017	Leerink Swann	Boost Price Target	Market Perform	$92.00 ➝ $93.00	N/A
10/13/2017	Piper Jaffray Companies	Reiterated Rating	Buy	$105.00	N/A
10/4/2017	Cowen	Reiterated Rating	Buy	$95.00	Low
7/26/2017	UBS	Downgrade	Hold	$85.00	Medium
7/26/2017	Oppenheimer	Downgrade	Outperform ➝ Market Perform	$90.00 ➝ $90.00	Low
7/17/2017	Deutsche Bank	Reiterated Rating	Buy	$90.00 ➝ $91.00	Low
7/4/2017	Citigroup	Reiterated Rating	Buy	$100.00	Low
5/21/2017	Sanford C. Bernstein	Reiterated Rating	Outperform	$88.00	Medium
11/25/2016	Atlantic Securities	Downgrade	Overweight ➝ Neutral		N/A
10/27/2016	Societe Generale	Reiterated Rating	Hold	$78.00	N/A
6/15/2016	SunTrust Banks	Reiterated Rating	Buy		N/A

(Data available from 5/25/2016 forward)

Eli Lilly And Co (NYSE:LLY) Earnings History and Estimates Chart

Earnings by Quarter for Eli Lilly And Co (NYSE:LLY)

Eli Lilly And Co (NYSE:LLY) Earnings Estimates

2018 EPS Consensus Estimate: $4.95

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2018	3	$1.08	$1.14	$1.11
Q2 2018	2	$1.25	$1.31	$1.28
Q3 2018	2	$1.17	$1.28	$1.23
Q4 2018	2	$1.30	$1.37	$1.34

Eli Lilly And Co (NYSE LLY) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
7/24/2018		$1.29					N/A
4/24/2018	Q1 2018	$1.13	$1.34	$5.5139 billion	$5.70 billion	View	N/A
1/31/2018	Q4 2017	$1.08	$1.14	$5.9349 billion	$6.1610 billion	View	N/A
10/24/2017	Q3 2017	$1.03	$1.05	$5.5181 billion	$5.6580 billion	View	N/A
7/25/2017	Q2 2017	$1.05	$1.11	$5.5985 billion	$5.8243 billion	View	N/A
4/25/2017	Q1 17	$0.96	$0.98	$5.2156 billion	$5.2280 billion	View	N/A
1/31/2017	Q416	$0.98	$0.95	$5.54 billion	$5.76 billion	View	N/A
10/25/2016	Q316	$0.96	$0.88	$4.23 billion	$5.19 billion	View	Listen
7/26/2016	Q216	$0.86	$0.86	$5.14 billion	$5.40 billion	View	Listen
4/26/2016	Q116	$0.85	$0.83	$4.82 billion	$4.87 billion	View	Listen
1/28/2016	Q415	$0.78	$0.78	$5.33 billion	$5.38 billion	View	Listen
10/22/2015	Q315	$0.76	$0.89	$4.99 billion	$4.96 billion	View	Listen
7/23/2015	Q215	$0.74	$0.90	$4.89 billion	$4.98 billion	View	Listen
4/23/2015	Q115	$0.76	$0.87	$4.62 billion	$4.64 billion	View	N/A
1/30/2015	Q414	$0.74	$0.75	$5.21 billion	$5.12 billion	View	N/A
10/23/2014	Q314	$0.66	$0.66	$4.83 billion	$4.88 billion	View	Listen
7/24/2014	Q214	$0.66	$0.68	$4.88 billion	$4.94 billion	View	N/A
4/24/2014	Q114	$0.70	$0.70	$4.78 billion	$4.68 billion	View	N/A
1/30/2014	Q413	$0.72	$0.74	$5.46 billion	$5.81 billion	View	Listen
10/23/2013	Q313	$1.04	$1.11	$5.76 billion	$5.77 billion	View	N/A
7/24/2013	Q2 2013	$1.01	$1.16	$5.82 billion	$5.93 billion	View	N/A
4/24/2013	Q1 2013	$1.05	$1.14	$5.66 billion	$5.60 billion	View	N/A
1/29/2013	Q4 2012	$0.82	$0.85	$5.78 billion	$5.96 billion	View	N/A
10/24/2012		$0.82	$0.79			View	N/A
7/25/2012		$0.76	$0.83			View	N/A
4/25/2012		$0.80	$0.92			View	N/A
1/31/2012		$0.80	$0.87			View	N/A
10/20/2011		$1.12	$1.13			View	N/A
7/21/2011		$1.18	$1.18			View	N/A
4/18/2011		$1.16	$1.24			View	N/A
1/27/2011		$1.10	$1.11			View	N/A
10/21/2010	Q3 2010	$1.15	$1.21			View	N/A
7/22/2010	Q2 2010	$1.11	$1.24			View	N/A
4/19/2010	Q1 2010	$1.11	$1.18			View	N/A
1/28/2010	Q4 2009	$0.92	$0.91			View	N/A
10/21/2009	Q3 2009	$1.02	$1.20			View	N/A
7/22/2009	Q2 2009	$1.02	$1.12			View	N/A
4/20/2009	Q1 2009	$0.99	$1.20			View	N/A
1/29/2009	Q4 2008	$1.05	$1.07			View	N/A
10/23/2008	Q3 2008	$1.01	$1.04			View	N/A
7/24/2008	Q2 2008	$0.99	$0.99			View	N/A
4/21/2008	Q1 2008	$0.95	$0.92			View	N/A
1/29/2008	Q4 2007	$0.89	$0.90			View	N/A

(Earnings results data provided by Zacks Investment Research)

Eli Lilly And Co (NYSE:LLY) Dividend Information

Eli Lilly And Co pays an annual dividend of $2.25 per share, with a dividend yield of 2.72%. LLY's next quarterly dividend payment will be made on Friday, June 8. The company has grown its dividend for the last 3 consecutive years and is increasing its dividend by an average of 2.00% each year. Eli Lilly And Co pays out 52.57% of its earnings out as a dividend.

Next Dividend:	6/8/2018
Annual Dividend:	$2.25
Dividend Yield:	2.72%
Dividend Growth:	2.00% (3 Year Average)
Payout Ratio(s):	52.57% (Trailing 12 Months of Earnings) 43.60% (Based on This Year's Estimates) 41.36% (Based on Next Year's Estimates) 40.57% (Based on Cash Flow)
Track Record:	3 Years of Consecutive Dividend Growth
Frequency:	Quarterly Dividend

Dividend Payments by Quarter for Eli Lilly And Co (NYSE:LLY)

Eli Lilly And Co (NYSE:LLY) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
5/7/2018	quarterly	$0.5625	2.86%	5/16/2018	5/17/2018	6/8/2018
12/11/2017	quarterly	$0.5625	2.59%	2/14/2018	2/15/2018	3/9/2018
10/16/2017	quarterly	$0.52	2.42%	11/14/2017	11/15/2017	12/8/2017
6/19/2017	quarterly	$0.52	2.51%	8/11/2017	8/15/2017	9/8/2017
5/1/2017	quarterly	$0.52	2.55%	5/11/2017	5/15/2017	6/9/2017
12/13/2016	quarterly	$0.52	3.03%	2/13/2017	2/15/2017	3/10/2017
10/17/2016	quarterly	$0.51	2.59%	11/10/2016	11/15/2016	12/9/2016
6/20/2016	quarterly	$0.51	2.81%	8/11/2016	8/15/2016	9/9/2016
5/2/2016	quarterly	$0.51	2.68%	5/11/2016	5/13/2016	6/10/2016
12/8/2015	quarterly	$0.51	2.43%	2/10/2016	2/12/2016	3/10/2016
10/19/2015	quarterly	$0.50	2.57%	11/10/2015	11/13/2015	12/10/2015
6/15/2015	quarterly	$0.50	2.42%	8/12/2015	8/14/2015	9/10/2015
5/4/2015	quarterly	$0.50	2.78%	5/14/2015	5/18/2015	6/10/2015
12/15/2014	quarterly	$0.50	2.89%	2/11/2015	2/13/2015	3/10/2015
10/20/2014	quarterly	$0.49	3.03%	11/12/2014	11/14/2014	12/10/2014
6/16/2014	quarterly	$0.49	3.31%	8/13/2014	8/15/2014	9/10/2014
5/5/2014	quarterly	$0.49	3.35%	5/13/2014	5/15/2014	6/10/2014
12/16/2013	quarterly	$0.49	3.98%	2/12/2014	2/14/2014	3/10/2014
10/21/2013	quarterly	$0.49	3.91%	11/13/2013	11/15/2013	12/10/2013
6/18/2013	quarterly	$0.49	3.82%	8/13/2013	8/15/2013	9/10/2013
5/6/2013	quarterly	$0.49	3.62%	5/14/2013	5/16/2013	6/10/2013
12/17/2012	quarterly	$0.49	3.96%	2/13/2013	2/15/2013	3/8/2013

(Data available from 1/1/2013 forward)

Eli Lilly And Co (NYSE LLY) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 0.11%
Institutional Ownership Percentage: 76.10%

Insider Trading History for Eli Lilly And Co (NYSE:LLY)

Institutional Ownership by Quarter for Eli Lilly And Co (NYSE:LLY)

Eli Lilly And Co (NYSE LLY) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
5/11/2018	Lilly Endowment Inc	Major Shareholder	Sell	140,000	$81.97	$11,475,800.00	122,755,804
5/3/2018	Jeffrey N Simmons	SVP	Sell	9,027	$78.50	$708,619.50
4/25/2018	Lilly Endowment Inc	Major Shareholder	Sell	180,000	$80.85	$14,553,000.00	122,896,904
4/16/2018	Susan Mahony	SVP	Sell	22,544	$80.09	$1,805,548.96	45,652
4/13/2018	Susan Mahony	SVP	Sell	5,165	$80.14	$413,923.10	45,652
3/16/2018	Joshua L Smiley	CFO	Sell	3,000	$79.20	$237,600.00	20,029
3/1/2018	Donald A Zakrowski	Insider	Sell	860	$76.50	$65,790.00
2/21/2018	Donald A Zakrowski	Insider	Sell	876	$77.55	$67,933.80	4,130
2/5/2018	Donald A Zakrowski	Insider	Sell	900	$81.09	$72,981.00	4,130
2/5/2018	Jeffrey N Simmons	SVP	Sell	9,625	$81.12	$780,780.00	152,120
12/13/2017	Lilly Endowment Inc	Major Shareholder	Sell	200,000	$88.20	$17,640,000.00	123,084,104
12/11/2017	Jeffrey N Simmons	SVP	Sell	12,500	$86.46	$1,080,750.00	124,522
12/4/2017	Susan Mahony	SVP	Sell	36,585	$86.18	$3,152,895.30	54,885
11/10/2017	Alfonso G Zulueta	SVP	Sell	2,003	$83.67	$167,591.01	43,580
10/4/2017	Lilly Endowment Inc	Major Shareholder	Sell	205,000	$86.81	$17,796,050.00
9/29/2017	Lilly Endowment Inc	Major Shareholder	Sell	195,000	$85.14	$16,602,300.00	123,513,247
9/15/2017	Lilly Endowment Inc	Major Shareholder	Sell	190,000	$82.53	$15,680,700.00	123,682,287
8/31/2017	Lilly Endowment Inc	Major Shareholder	Sell	180,000	$81.06	$14,590,800.00	123,865,804
7/31/2017	Lilly Endowment Inc	Major Shareholder	Sell	220,000	$83.09	$18,279,800.00	124,049,283
6/22/2017	Lilly Endowment Inc	Major Shareholder	Sell	210,000	$84.43	$17,730,300.00	124,265,804
6/20/2017	Lilly Endowment Inc	Major Shareholder	Sell	215,000	$83.05	$17,855,750.00	124,475,804
6/12/2017	Melissa S Barnes	Insider	Sell	1,900	$80.78	$153,482.00	14,041
6/9/2017	Michael J Harrington	VP	Sell	22,833	$79.97	$1,825,955.01	62,056
5/4/2017	Enrique A Conterno	SVP	Sell	25,000	$82.76	$2,069,000.00	114,217
3/30/2017	Lilly Endowment Inc	Major Shareholder	Sell	210,000	$84.67	$17,780,700.00	124,690,804
2/17/2017	Lilly Endowment Inc	Major Shareholder	Sell	230,000	$80.27	$18,462,100.00	125,125,804
2/6/2017	Alfonso G Zulueta	SVP	Sell	15,000	$77.66	$1,164,900.00	45,583
2/3/2017	Derica W Rice	EVP	Sell	11,162	$77.14	$861,036.68	58,443
2/2/2017	Donald A Zakrowski	Insider	Sell	2,000	$77.52	$155,040.00	886
2/1/2017	Lilly Endowment Inc	Major Shareholder	Sell	220,000	$77.35	$17,017,000.00	125,359,047
12/16/2016	Lilly Endowment Inc	Major Shareholder	Sell	200,000	$72.59	$14,518,000.00	125,649,408
12/16/2016	Melissa S Barnes	Insider	Sell	2,093	$82.23	$172,107.39	8,169
12/16/2016	R David Hoover	Director	Buy	500	$71.85	$35,925.00	33,504
12/16/2016	Susan Mahony	SVP	Sell	20,242	$72.65	$1,470,581.30	67,802
10/5/2016	Maria A Crowe	Insider	Sell	2,248	$81.37	$182,919.76	94,319
8/15/2016	Jackson P Tai	Director	Buy	5,773	$80.43	$464,322.39	42,306
8/12/2016	Jackson P Tai	Director	Buy	2,560	$80.42	$205,875.20	42,110
7/29/2016	Lilly Endowment Inc	Major Shareholder	Sell	205,000	$82.94	$17,002,700.00	125,775,804
7/28/2016	Donald A Zakrowski	Insider	Sell	1,213	$83.16	$100,873.08	1,300
7/28/2016	Lilly Endowment Inc	Major Shareholder	Sell	240,000	$82.87	$19,888,800.00	126,020,570
7/12/2016	Lilly Endowment Inc	Major Shareholder	Sell	210,000	$79.54	$16,703,400.00	126,220,804
7/7/2016	Lilly Endowment Inc	Major Shareholder	Sell	225,000	$79.14	$17,806,500.00	126,442,509
6/30/2016	Lilly Endowment Inc	Major Shareholder	Sell	215,000	$78.46	$16,868,900.00	126,808,704
6/29/2016	Lilly Endowment Inc	Major Shareholder	Sell	220,000	$77.86	$17,129,200.00	126,963,785
6/10/2016	Melissa S Barnes	SVP	Sell	992	$73.77	$73,179.84	10,710
5/31/2016	Lilly Endowment Inc	Major Shareholder	Sell	200,000	$75.12	$15,024,000.00	127,090,804
5/12/2016	Jackson P Tai	Director	Buy	1,080	$75.75	$81,810.00	40,600
5/12/2016	Lilly Endowment Inc	Major Shareholder	Sell	190,000	$75.86	$14,413,400.00	127,295,910
5/2/2016	Donald A Zakrowski	CAO	Sell	1,600	$75.86	$121,376.00	3,113
4/29/2016	Lilly Endowment Inc	Major Shareholder	Sell	180,000	$75.44	$13,579,200.00	127,481,005
4/27/2016	Alfonso G Zulueta	SVP	Sell	12,000	$76.27	$915,240.00	45,101
4/8/2016	Lilly Endowment Inc	Major Shareholder	Sell	200,000	$74.29	$14,858,000.00	127,660,804
2/5/2016	Stephen F Fry	SVP	Sell	15,230	$78.87	$1,201,190.10	59,690
2/3/2016	David A. Ricks	SVP	Sell	5,733	$77.66	$445,224.78	79,403
2/3/2016	Derica W. Rice	CFO	Sell	10,483	$77.78	$815,367.74	36,931
2/1/2016	Jackson P Tai	Director	Buy	3,170	$78.62	$249,225.40	39,487
1/29/2016	Alfonso G Zulueta	SVP	Sell	5,000	$78.75	$393,750.00	57,101
12/21/2015	Lilly Endowment Inc	Major Shareholder	Sell	205,000	$86.00	$17,630,000.00	127,860,804
12/15/2015	Lilly Endowment Inc	Major Shareholder	Sell	215,000	$85.60	$18,404,000.00	128,065,804
12/9/2015	Enrique A Conterno	VP	Sell	25,000	$83.88	$2,097,000.00	88,131
12/2/2015	Lilly Endowment Inc	major shareholder	Sell	210,000	$85.09	$17,868,900.00	128,280,804
11/20/2015	Lilly Endowment Inc	major shareholder	Sell	205,000	$84.54	$17,330,700.00	128,490,804
10/29/2015	Lilly Endowment Inc	major shareholder	Sell	200,000	$82.28	$16,456,000.00	128,695,804
10/9/2015	Lilly Endowment Inc	major shareholder	Sell	215,000	$85.86	$18,459,900.00	128,895,804
10/5/2015	Lilly Endowment Inc	major shareholder	Sell	260,000	$86.46	$22,479,600.00	129,110,804
9/18/2015	Lilly Endowment Inc	major shareholder	Sell	250,000	$89.04	$22,260,000.00	129,370,804
6/10/2015	Lilly Endowment Inc	Major Shareholder	Sell	210,000	$82.39	$17,301,900.00
6/4/2015	Lilly Endowment Inc	Major Shareholder	Sell	200,000	$77.90	$15,580,000.00
5/29/2015	Jeffrey N Simmons	SVP	Sell	20,000	$78.08	$1,561,600.00
5/20/2015	Lilly Endowment Inc	Major Shareholder	Sell	190,000	$73.43	$13,951,700.00
5/15/2015	Lilly Endowment Inc	Major Shareholder	Sell	200,000	$72.83	$14,566,000.00
5/8/2015	Lilly Endowment Inc	Major Shareholder	Sell	195,000	$73.28	$14,289,600.00
5/1/2015	Lilly Endowment Inc	Major Shareholder	Sell	200,000	$73.09	$14,618,000.00
3/30/2015	Lilly Endowment Inc	Major Shareholder	Sell	180,000	$73.94	$13,309,200.00
3/23/2015	Lilly Endowment Inc	Major Shareholder	Sell	190,000	$76.97	$14,624,300.00
3/9/2015	Stephen F Fry	SVP	Sell	4,000	$69.27	$277,080.00
2/4/2015	David A Ricks	SVP	Sell	3,147	$69.99	$220,258.53
2/4/2015	Derica W Rice	CFO	Sell	5,316	$70.00	$372,120.00
2/4/2015	Jan M Lundberg	EVP	Sell	11,085	$70.08	$776,836.80
2/3/2015	Jan M Lundberg	EVP	Sell	121,711	$70.78	$8,614,704.58
2/2/2015	David A Ricks	SVP	Sell	4,769	$71.51	$341,031.19
2/2/2015	Derica W Rice	CFO	Sell	10,068	$71.84	$723,285.12
12/4/2014	Lilly Endowment Inc	Major Shareholder	Sell	190,000	$71.92	$13,664,800.00
12/2/2014	Lilly Endowment Inc	Major Shareholder	Sell	180,000	$70.14	$12,625,200.00
11/13/2014	Lilly Endowment Inc	Major Shareholder	Sell	200,000	$67.73	$13,546,000.00
11/5/2014	Lilly Endowment Inc	Major Shareholder	Sell	180,000	$67.00	$12,060,000.00
11/4/2014	Fionnuala M Walsh	SVP	Sell	15,000	$67.00	$1,005,000.00
11/3/2014	Enrique A Conterno	VP	Sell	5,000	$66.03	$330,150.00
10/31/2014	Fionnuala M Walsh	SVP	Sell	7,376	$66.58	$491,094.08
10/31/2014	Lilly Endowment Inc	Major Shareholder	Sell	190,000	$66.40	$12,616,000.00
10/30/2014	Lilly Endowment Inc	Major Shareholder	Sell	175,000	$66.58	$11,651,500.00
10/24/2014	Maria A Crowe	Insider	Sell	2,750	$65.77	$180,867.50
10/6/2014	Lilly Endowment Inc	Major Shareholder	Sell	210,000	$65.63	$13,782,300.00
10/1/2014	Enrique A Conterno	VP	Sell	5,000	$64.86	$324,300.00
9/30/2014	Lilly Endowment Inc	Major Shareholder	Sell	200,000	$65.07	$13,014,000.00
9/10/2014	Lilly Endowment Inc	Major Shareholder	Sell	210,000	$64.77	$13,601,700.00
9/3/2014	Lilly Endowment Inc	Major Shareholder	Sell	200,000	$63.99	$12,798,000.00
9/2/2014	Enrique A Conterno	VP	Sell	5,000	$63.60	$318,000.00
7/29/2014	Lilly Endowment Inc	Major Shareholder	Sell	250,000	$63.03	$15,757,500.00
7/28/2014	Susan Mahony	SVP	Sell	2,065	$63.30	$130,714.50
7/25/2014	Enrique A Conterno	VP	Sell	10,000	$63.79	$637,900.00
7/25/2014	Susan Mahony	SVP	Sell	30,000	$63.90	$1,917,000.00
7/1/2014	Lilly Endowment Inc	Major Shareholder	Sell	235,000	$62.30	$14,640,500.00
6/25/2014	Lilly Endowment Inc	Major Shareholder	Sell	245,000	$62.68	$15,356,600.00
6/20/2014	Lilly Endowment Inc	Major Shareholder	Sell	230,000	$61.55	$14,156,500.00
6/16/2014	Lilly Endowment Inc	Major Shareholder	Sell	200,000	$58.73	$11,746,000.00
6/5/2014	Lilly Endowment Inc	Major Shareholder	Sell	190,000	$59.53	$11,310,700.00
5/21/2014	Lilly Endowment Inc	major shareholder	Sell	230,000	$58.90	$13,547,000.00	134,690,804
5/12/2014	Jackson Tai	Director	Buy	17,157	$59.19	$1,015,522.83	32,180
5/12/2014	Lilly Endowment Inc	major shareholder	Sell	210,000	$59.33	$12,459,300.00	134,920,804
5/6/2014	Lilly Endowment Inc	major shareholder	Sell	190,000	$58.79	$11,170,100.00	135,130,804
4/29/2014	Lilly Endowment Inc	major shareholder	Sell	200,000	$59.43	$11,886,000.00	135,320,804
4/28/2014	Lilly Endowment Inc	major shareholder	Sell	150,000	$58.64	$8,796,000.00	135,520,804
8/15/2013	Enrique Conterno	VP	Sell	5,000	$53.79	$268,950.00	57,177
7/29/2013	Jacques Tapiero	SVP	Sell	7,500	$53.74	$403,050.00
7/15/2013	Enrique A Conterno	VP	Sell	5,000	$51.43	$257,150.00
6/17/2013	Enrique A Conterno	VP	Sell	5,000	$52.45	$262,250.00
5/15/2013	Enrique A Conterno	VP	Sell	5,000	$56.15	$280,750.00
5/10/2013	Jeffrey N Simmons	SVP	Sell	10,000	$54.49	$544,900.00
3/26/2013	Susan Mahony	SVP	Sell	5,000	$56.00	$280,000.00

(Data available from 1/1/2013 forward)

Eli Lilly And Co (NYSE LLY) News Headlines

Source:

Date	Headline
	Why Is Eli Lilly (LLY) Up 2.7% Since Its Last Earnings Report? finance.yahoo.com - May 24 at 5:24 PM
	FDA Confirms September Action Date for Teva's Migraine Drug finance.yahoo.com - May 24 at 5:24 PM
	Sue Mahony to Retire as President of Lilly Oncology finance.yahoo.com - May 23 at 5:22 PM
	Analyst Recommendations for Eli Lilly on May 17 finance.yahoo.com - May 23 at 8:32 AM
	FDA OKs expanded label for Lilly's Taltz seekingalpha.com - May 22 at 4:59 PM
	Eli Lilly’s Cardiovascular Products in Q1 2018 finance.yahoo.com - May 22 at 4:59 PM
	Lilly's Taltz® (ixekizumab) Receives the First U.S. FDA Approval for Label Update to Include Data for Psoriasis Involving the Genital Area finance.yahoo.com - May 22 at 4:59 PM
	Why Did JNJ Scrap Its Alzheimer’s Drug Mid-Stage Trial? finance.yahoo.com - May 22 at 4:59 PM
	Eli Lilly’s Elanco in Q1 2018 finance.yahoo.com - May 22 at 4:59 PM
	Barclays Analysts Give Eli Lilly and (LLY) a $98.00 Price Target www.americanbankingnews.com - May 22 at 9:45 AM
	Global Schizophrenia Market Growth Opportunities: Alkermes, Pfizer Inc., Allergan plc, Eli Lilly and Company www.marketwatch.com - May 22 at 8:32 AM
	Eli Lilly’s Oncology Products in Q1 2018 finance.yahoo.com - May 22 at 8:32 AM
	Eli Lilly’s Neuroscience Products in Q1 2018 finance.yahoo.com - May 21 at 5:00 PM
	Eli Lilly’s Human Pharmaceuticals Business in Q1 2018 finance.yahoo.com - May 21 at 8:32 AM
	Autoimmune Disease Treatment Market 2018 Outlook \| Professional Survey Upcoming Treatments, Challenges, Scope, Analysis and Forecast Till 2023 www.marketwatch.com - May 19 at 8:29 AM
	Trump’s New Health and Human Services Secretary Is a Joyful Regulator www.nytimes.com - May 19 at 8:29 AM
	$1.34 EPS Expected for Eli Lilly and Company (LLY) This Quarter www.americanbankingnews.com - May 18 at 9:23 PM
	Eli Lilly’s Revenue Trend in Q1 2018 finance.yahoo.com - May 18 at 5:37 PM
	Lawful But Never Substantial: Off-Label Use and Contributory Infringement in Hatch-Waxman Litigation finance.yahoo.com - May 18 at 9:04 AM
	U.S. FDA approves Amgen migraine drug, price set at $6900/yr finance.yahoo.com - May 18 at 9:04 AM
	Brokers Set Expectations for Eli Lilly and Company's FY2022 Earnings (LLY) www.americanbankingnews.com - May 18 at 8:43 AM
	Possible Shift in Medicare Drug Organization May Give Pharma Heartburn finance.yahoo.com - May 17 at 5:58 PM
	Eli Lilly & Co. (LLY) Says Data at ASCO Illustrate Patient-Driven Advances in Cancer Care www.streetinsider.com - May 17 at 8:41 AM
	3 Things In Biotech, May 16: Lilly's No Headache, Aerie Eye's A Finish, Rexahn Swaps In Pancreatic Cancer seekingalpha.com - May 17 at 8:41 AM
	Wired News – Eli Lilly’s Galcanezumab Met Primary Endpoint in Phase-3 Study for Prevention of Episodic Cluster Headache finance.yahoo.com - May 17 at 8:41 AM
	Eli Lilly's Cluster Headache Candidate Succeeds in Phase III finance.yahoo.com - May 16 at 5:21 PM
	Eli Lilly's Cluster Headache Candidate Succeeds in Phase III finance.yahoo.com - May 16 at 5:21 PM
	Lilly Data at ASCO Illustrate Patient-Driven Advances in Cancer Care finance.yahoo.com - May 16 at 5:21 PM
	Eli Lilly and (LLY) Given a $82.00 Price Target at Credit Suisse Group www.americanbankingnews.com - May 16 at 3:21 PM
	Eli Lilly's Positive Phase 3 Results Along With Recent Acquisitions Makes It A Force To Be Reckoned With seekingalpha.com - May 16 at 8:42 AM
	Global Lung Cancer Therapeutic Market Growth Opportunities: Eli Lilly and company, AstraZeneca Plc www.marketwatch.com - May 16 at 8:42 AM
	Eli Lilly (LLY) to Buy AurKa Pharma, Expand Cancer Pipeline finance.yahoo.com - May 15 at 5:35 PM
	An Update on Teva’s Highly Anticipated Migraine Drug finance.yahoo.com - May 15 at 5:35 PM
	Global Erectile Dysfunction Market Growth Opportunities: Endo Pharmaceuticals, Eli Lilly And Company www.marketwatch.com - May 15 at 8:51 AM
	Lilly (LLY) Says Galcanezumab Met Primary Endpoint in Phase 3 Study for Prevention of Episodic Cluster Headache www.streetinsider.com - May 15 at 8:51 AM
	Lilly's Galcanezumab Meets Primary Endpoint in Phase 3 Study Evaluating Galcanezumab for the Prevention of Episodic Cluster Headache finance.yahoo.com - May 15 at 8:51 AM
	Eli Lilly's galcanezumab successful in late-stage cluster headache study seekingalpha.com - May 15 at 8:51 AM
	BRIEF-Eli Lilly Says Phase 3 Study For Patients With Chronic Cluster Headache Did Not Meet Its Primary Endpoint www.reuters.com - May 15 at 8:51 AM
	Eli Lilly and Company (LLY) Major Shareholder Lilly Endowment Inc Sells 140,000 Shares www.americanbankingnews.com - May 14 at 4:19 PM
	Celgene And Otezla Are Cracking seekingalpha.com - May 14 at 8:52 AM
	Lilly To Buy AurKa Pharma www.nasdaq.com - May 14 at 8:52 AM
	BRIEF-Eli Lilly To Acquire Aurka Pharma www.reuters.com - May 14 at 8:52 AM
	Global Diabetic Neuropathy Market Opportunities 2018: Eli Lilly and Company, Cephalon , Boehringer Ingelheim GmbH, Meda Pharma GmbH www.marketwatch.com - May 14 at 8:52 AM
	Lilly (LLY) to Acquire AurKa Pharma for $110M Upfront, Plus up to $465M in Milestones www.streetinsider.com - May 14 at 8:52 AM
	Eli Lilly to acquire AurKa Pharma for up to $545M seekingalpha.com - May 14 at 8:52 AM
	Eli Lilly to buy cancer drug developer AurKa Pharma www.reuters.com - May 14 at 8:52 AM
	Lilly to Acquire AurKa Pharma finance.yahoo.com - May 14 at 8:52 AM
	Eli Lilly Takes $7M Gamble On Global Health Working... In Indiana finance.yahoo.com - May 14 at 8:52 AM
	Lilly to buy cancer drug developer AurKa Pharma finance.yahoo.com - May 14 at 8:52 AM
	Eli Lilly and Company (LLY) Given Consensus Rating of "Hold" by Analysts www.americanbankingnews.com - May 13 at 5:31 PM

Eli Lilly And Co (NYSE:LLY) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

Eli Lilly And Co (NYSE:LLY) Income Statement, Balance Sheet and Cash Flow Statement

Eli Lilly And Co (NYSE LLY) Stock Chart for Friday, May, 25, 2018

Loading chart…

This page was last updated on 5/25/2018 by MarketBeat.com Staff